Cargando…
P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431464/ http://dx.doi.org/10.1097/01.HS9.0000971004.26914.cb |
| _version_ | 1785091208989638656 |
|---|---|
| author | Harrison, Claire Patriarca, Andrea Gupta, Vikas Palandri, Francesca Devos, Timothy Rampal, Raajit K Talpaz, Moshe Vannucchi, Alessandro Kuykendall, Andrew Kiladjian, Jean-Jacques Verstovsek, Srdan Mesa, Ruben Colak, Gozde Dutta, Soumik Klein, Sandra Cui, Jie Chang, Tzuu-Wang Mascarenhas, John |
| author_facet | Harrison, Claire Patriarca, Andrea Gupta, Vikas Palandri, Francesca Devos, Timothy Rampal, Raajit K Talpaz, Moshe Vannucchi, Alessandro Kuykendall, Andrew Kiladjian, Jean-Jacques Verstovsek, Srdan Mesa, Ruben Colak, Gozde Dutta, Soumik Klein, Sandra Cui, Jie Chang, Tzuu-Wang Mascarenhas, John |
| author_sort | Harrison, Claire |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431464 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104314642023-08-17 P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS Harrison, Claire Patriarca, Andrea Gupta, Vikas Palandri, Francesca Devos, Timothy Rampal, Raajit K Talpaz, Moshe Vannucchi, Alessandro Kuykendall, Andrew Kiladjian, Jean-Jacques Verstovsek, Srdan Mesa, Ruben Colak, Gozde Dutta, Soumik Klein, Sandra Cui, Jie Chang, Tzuu-Wang Mascarenhas, John Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431464/ http://dx.doi.org/10.1097/01.HS9.0000971004.26914.cb Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Harrison, Claire Patriarca, Andrea Gupta, Vikas Palandri, Francesca Devos, Timothy Rampal, Raajit K Talpaz, Moshe Vannucchi, Alessandro Kuykendall, Andrew Kiladjian, Jean-Jacques Verstovsek, Srdan Mesa, Ruben Colak, Gozde Dutta, Soumik Klein, Sandra Cui, Jie Chang, Tzuu-Wang Mascarenhas, John P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title | P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title_full | P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title_fullStr | P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title_full_unstemmed | P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title_short | P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS |
| title_sort | p1027: updated durability of response and safety in manifest arm 3: pelabresib (cpi-0610) combined with ruxolitinib for jak inhibitor treatment-naïve patients with myelofibrosis |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431464/ http://dx.doi.org/10.1097/01.HS9.0000971004.26914.cb |
| work_keys_str_mv | AT harrisonclaire p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT patriarcaandrea p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT guptavikas p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT palandrifrancesca p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT devostimothy p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT rampalraajitk p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT talpazmoshe p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT vannucchialessandro p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT kuykendallandrew p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT kiladjianjeanjacques p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT verstovseksrdan p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT mesaruben p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT colakgozde p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT duttasoumik p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT kleinsandra p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT cuijie p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT changtzuuwang p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis AT mascarenhasjohn p1027updateddurabilityofresponseandsafetyinmanifestarm3pelabresibcpi0610combinedwithruxolitinibforjakinhibitortreatmentnaivepatientswithmyelofibrosis |